A natural cruciferous-vegetable compound that reliably shifts estrogen processing toward a gentler form. One small placebo-controlled study found it helped precancerous cervical changes regress. Broader cancer-prevention, hormone-balance, and longevity claims rest only on cell and animal data. Generally well tolerated, inexpensive, and easy to obtain, but proven disease benefit remains unestablished. (Full Review)

Protocol

Dose

200–400 mg/day I3C

Studied range; DIM products dosed lower (~75–200 mg/day). Start low (~200 mg) and titrate.

Form

I3C or enhanced DIM

Parent I3C gives the full natural product mixture; bioavailability-enhanced DIM gives a defined compound and predictable dose.

Timing

With food, divided doses

Taken with food to improve tolerability and supply stomach acid for conversion; twice daily with meals for stable exposure. No circadian preference.

Time to effect

Estrogen-metabolism shift

Days to weeks

The measurable biomarker shift.

Cervical-lesion regression

~12 weeks

Horizon over which the clinical endpoint was assessed.

Any clinical change

Multi-week to multi-month

Realistic horizon for any clinical change.

Benefits

Medium: Favorable shift in estrogen metabolism; regression of cervical precancerous lesions

Low: Support in recurrent respiratory papillomatosis; reduction of breast density and hormone-related breast markers; carcinogen detoxification support

Speculative: Senolytic and longevity-related effects; metabolic and anti-inflammatory benefits

Contraindications

Pregnancy and breastfeeding

Active hormone-sensitive cancer

Children

Key Interactions

CYP1A2-substrate drugs (theophylline, clozapine, olanzapine, tizanidine)

Caffeine

Acid-suppressing OTC drugs (proton-pump inhibitors, antacids)

DIM products and other CYP1A modulators (resveratrol, herbal extracts)

Additive estrogen-metabolism supplements (calcium-D-glucarate, sulforaphane, DIM)

Hormone therapies (oral contraceptives, hormone-replacement therapy, tamoxifen)

Risk & Side Effects

Medium: Gastrointestinal upset; possible tumor promotion with mistimed use

Low: Liver enzyme effects; balance and neurological symptoms at high doses

Speculative: Thyroid concern; hormonal effects in vulnerable populations

Monitoring

Marker	Target	Why
2-OHE : 16α-OHE ratio (urine)	≥ 2.0	Tracks the primary intended effect of I3C
ALT / AST (liver enzymes)	ALT < 25 U/L (men), < 20 U/L (women)	Detects any liver enzyme effect from CYP1 induction at higher doses
TSH	0.5–2.5 mIU/L	Screens for any thyroid impact, addressing the goitrogen concern
Estradiol (serum)	Cycle- and sex-appropriate	Provides hormonal context for an estrogen-modulating agent
Iodine (urinary)	100–199 µg/L (spot)	Confirms iodine sufficiency that offsets the theoretical thyroid risk

Cadence: Baseline before first dose; at ~8–12 weeks after starting; then every 6–12 months on sustained or higher-dose use.

Qualitative Assessment

Energy levels and general well-being
Premenstrual and menstrual symptom changes (in women using it for hormone-related goals)
Digestive comfort (to catch dose-related gastrointestinal upset early)
Any neurological symptoms such as balance disturbance (a flag to reduce dose)

Indole-3-Carbinol for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment